tiprankstipranks
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (SFOSF)
OTHER OTC:SFOSF
US Market
SFOSF
Shanghai Fosun Pharmaceutical (Group) Co
RESEARCH TOOLSreports

Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Income Statement

26 Followers

Shanghai Fosun Pharmaceutical (Group) Co Income Statement

Last quarter (Q4 2025), Shanghai Fosun Pharmaceutical (Group) Co's total revenue was ¥21.70B, an increase of 107.72% from the same quarter last year. In Q4, Shanghai Fosun Pharmaceutical (Group) Co's net income was ¥1.64B. See Shanghai Fosun Pharmaceutical (Group) Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 40.42B¥ 41.07B¥ 41.40B¥ 43.95B¥ 39.01B
Gross Profit
¥ 20.16B¥ 19.70B¥ 19.68B¥ 20.78B¥ 18.78B
Operating Expenses
¥ 17.63B¥ 15.46B¥ 16.50B¥ 17.15B¥ 16.06B
Depreciation and Amortization
¥ 3.63B¥ 3.00B¥ 2.97B¥ 2.34B¥ 1.83B
EBITDA
¥ 6.16B¥ 8.60B¥ 7.55B¥ 7.87B¥ 8.70B
Operating Income
¥ 2.54B¥ 4.25B¥ 3.31B¥ 8.30B¥ 6.31B
Other Income/Expenses
¥ 2.44B¥ -75.82M¥ -42.94M¥ -82.27M¥ -259.90M
Pretax Income
¥ 4.98B¥ 4.17B¥ 3.26B¥ 4.57B¥ 6.05B
Net Income
¥ 3.28B¥ 2.77B¥ 2.39B¥ 3.73B¥ 4.73B
Per Share Metrics
Basic EPS
¥ 1.24¥ 1.04¥ 0.89¥ 1.43¥ 1.85
Diluted EPS
¥ 1.24¥ 1.04¥ 0.89¥ 1.43¥ 1.85
Weighted Average Shares Outstanding
 2.65B 2.67B 2.68B 2.61B 2.56B
Weighted Average Shares Outstanding (Diluted)
 2.65B 2.67B 2.67B 2.61B 2.56B
Currency in CNY

Shanghai Fosun Pharmaceutical (Group) Co Earnings and Revenue History